Amaria RN, Haymaker C, Forget M-A, et al. TGF-β dominant negative receptor (TGF-DNRII) and NGFR-transduced tumour infiltrating lymphocytes (TIL) and high dose interleukin-2 (IL-2) in patients (pts) with metastatic melanoma (MM). SMR 2017, abstract SMR04-1.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker